# FDA Summary: Temozolomide and Bevacizumab for GBM

## Temozolomide (Temodar) - FDA Information

### Approved Indications
- **Newly diagnosed glioblastoma multiforme**: Concurrent with radiotherapy, then maintenance
- **Recurrent anaplastic astrocytoma**: Previously treated patients
- **Initial approval**: 1999 (recurrent), 2005 (newly diagnosed)

### FDA-Approved Dosing

#### Newly Diagnosed GBM
**Concomitant Phase (with radiotherapy)**
- **Dose**: 75 mg/m² daily
- **Duration**: Up to 49 days
- **Administration**: Oral, on empty stomach
- **Monitoring**: Weekly CBC

**Maintenance Phase**
- **Cycle 1**: 150 mg/m² × 5 days every 28 days
- **Cycles 2-6**: 200 mg/m² × 5 days (if cycle 1 tolerated)
- **Maximum**: 6 cycles in original approval

#### Recurrent Anaplastic Astrocytoma
- **Dose**: 150 mg/m² × 5 days every 28 days
- **Escalation**: To 200 mg/m² if tolerated
- **Duration**: Until progression or toxicity

### FDA Safety Information

#### Contraindications
- Hypersensitivity to temozolomide or dacarbazine
- Severe bone marrow suppression

#### Black Box Warnings
None specified for temozolomide

#### Common Adverse Reactions (≥20%)
- Nausea (49-53%)
- Vomiting (29-42%)
- Headache (23-41%)
- Fatigue (34-61%)
- Constipation (22-33%)
- Alopecia (55-69%)

#### Serious Adverse Reactions
- Myelosuppression (Grade 3-4: ~20%)
- Pneumocystis pneumonia
- Secondary malignancies
- Hepatotoxicity

### FDA Monitoring Requirements
- **Baseline**: CBC, liver function
- **During treatment**: Weekly CBC (concomitant phase)
- **Maintenance**: CBC on day 22 and 29 of each cycle

## Bevacizumab (Avastin) - FDA Information

### Approved Indications for GBM
- **Recurrent glioblastoma**: Adult patients (accelerated approval 2009)
- **NOT approved**: For newly diagnosed GBM

### FDA-Approved Dosing for GBM
- **Standard dose**: 10 mg/kg IV every 2 weeks
- **Infusion time**: 90 min (first), then 60 min, then 30 min if tolerated
- **Duration**: Until disease progression or unacceptable toxicity

### FDA Safety Information

#### Black Box Warnings
1. **Gastrointestinal perforation**: 0.3-2.4% incidence
2. **Surgery and wound healing complications**: Increased risk
3. **Hemorrhage**: Including CNS hemorrhage (Grade ≥3: 2.5% in GBM)

#### Contraindications
- Recent hemoptysis (≥2.5 mL red blood)
- Serious bleeding events

#### Warnings and Precautions
1. **Hypertension**: Monitor BP, manage with antihypertensives
2. **Proteinuria**: Monitor urine protein
3. **Arterial thromboembolic events**: Higher risk in GBM patients
4. **Ovarian failure**: In premenopausal women
5. **Congestive heart failure**: Monitor cardiac function

#### GBM-Specific Safety Data
- **Arterial thromboembolic events**: Grade ≥3 in 5% (vs 1% control)
- **CNS hemorrhage**: 2.5% Grade ≥3
- **Intracranial hemorrhage**: Fatal in some cases

### FDA Dose Modifications
- **No dose reductions recommended**
- **Hold treatment**: For toxicity management
- **Permanently discontinue**: For severe reactions

## FDA Clinical Trial Data

### Temozolomide Pivotal Trials
**EORTC 26981/22981 Study**
- **Population**: 573 patients with newly diagnosed GBM
- **Primary endpoint**: Overall survival
- **Results**: 14.6 vs 12.1 months (HR: 0.63, P<0.001)
- **PFS**: 6.9 vs 5.0 months

### Bevacizumab Pivotal Trials
**AVAglio Trial (Phase III)**
- **Population**: 921 patients with newly diagnosed GBM
- **Design**: Bevacizumab + RT/TMZ vs placebo + RT/TMZ
- **Primary endpoint**: Overall survival (not met)
- **PFS**: 10.6 vs 6.2 months (HR: 0.64, P<0.001)

**RTOG 0825 Trial (Phase III)**
- **Population**: 637 patients with newly diagnosed GBM
- **Results**: Similar to AVAglio - PFS benefit, no OS benefit
- **Conclusion**: Led to FDA not approving for newly diagnosed GBM

### Recurrent GBM Studies (Bevacizumab)
**Study 007 (Single-arm)**
- **Population**: 85 patients with recurrent GBM
- **Response rate**: 25.9%
- **Duration of response**: 4.2 months
- **Basis**: For accelerated approval

## FDA Labeling Updates

### Recent Label Changes (2022)
- **Bevacizumab**: Updated safety information
- **Temozolomide**: Stability and storage updates
- **Monitoring**: Enhanced recommendations

### Post-Market Requirements
- **Temozolomide**: Long-term safety studies
- **Bevacizumab**: Confirmatory trials for recurrent GBM

## FDA Guidance Documents

### Dosing in Special Populations

#### Renal Impairment
- **Temozolomide**: No dose adjustment for mild-moderate impairment
- **Bevacizumab**: No specific dose adjustments

#### Hepatic Impairment
- **Temozolomide**: Use caution in severe impairment
- **Bevacizumab**: No specific dose adjustments

#### Elderly Patients
- **Temozolomide**: Age-related toxicity considerations
- **Bevacizumab**: Higher risk of arterial events

#### Pediatric Use
- **Temozolomide**: Safety/efficacy not established <3 years
- **Bevacizumab**: Safety/efficacy not established in pediatrics

## FDA Risk Evaluation and Mitigation Strategies (REMS)
- **Temozolomide**: No REMS required
- **Bevacizumab**: No REMS required
- **Monitoring**: Standard pharmacovigilance

## FDA Drug Interactions

### Temozolomide
- **Valproic acid**: May decrease clearance
- **Live vaccines**: Avoid during treatment
- **Minimal CYP interactions**: Non-enzymatic metabolism

### Bevacizumab
- **Chemotherapy**: Additive toxicities possible
- **Antihypertensives**: May need adjustment
- **Anticoagulants**: Increased bleeding risk

## Current FDA Status (2024)
- **Temozolomide**: Fully approved for indicated uses
- **Bevacizumab**: Approved for recurrent GBM only
- **Ongoing studies**: Post-market surveillance
- **Combination approval**: Not approved for newly diagnosed GBM

*Based on FDA Orange Book, prescribing information, and clinical review documents*